KalVista Pharma

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Kalvista Pharmaceuticals reported "overwhelmingly positive" results for its hereditary angioedema study on Tuesday, and the biotech stock rocketed to a five-year high. The post Kalvista Rockets To 5-Year High On 'Overwhelmingly Positive' Test Results appeared first on Investor's Business Daily.

Kalvista Rockets To 5-Year High On 'Overwhelmingly Positive' Test Results

The stock price of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) is trading at over 100% pre-market. This is why it happened.

KALV Stock Price Increases Over 100% Pre-Market: Why It Happened

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) attacks. “We are very excited to share this positiv

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

Ascendis Pharma

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical and medical device companies. Dr. Cha was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND) and KalVista Pharmaceuticals (NASDAQ: KALV), and has served on the boards of Aclari

Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?

KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on its franchise of oral therapies for treatment of hereditary angioedema (HAE). “We have completed enrollment of our Phase 2 trial for our oral on-demand HAE treatment, KVD900, and remain on track to deliver data before the end of

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference

Stemline Therapeutics

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost more than 59% over the past 52 weeks through April 10.

Wall Street Recommends Buying These 2 Falling Knives: KALV & STML

Wall Street Recommends Buying These 2 Falliing Knives

DaVita

Ensign Group

MEI Pharma

ResMed

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

CareDx

Calavo Growers

Darling Ingredients

Simply Good Foods

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

5 Defensive Stocks to Counter Coronavirus Scare

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

Will KalVista Continue to Surge Higher?

Amneal Pharmaceuticals

Collegium Pharmaceutical

Matinas BioPharma Hlds

Prospects Appear Bright for Small Drug Industry in 2020

Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are seen moving to the downside Monday.

KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KalVista Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KalVista Pharmaceuticals Enters Oversold Territory

FedEx

Heron Therapeutics

Immunomedics

VBI Vaccines

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

5 Stocks to Buy Based on Insider Buying

KalVista Group Sees Hammer Chart Pattern: Time to Buy?

KALV is an early stage company without much efficacy data, but early data for its drug candidates are promising.

KalVista: An Early Stage Company Doing Things The Right Way

Clinical-stage biopharma KalVista Pharmaceuticals has lost approximately 40% of its value since early April as it entered a news vacuum.

KalVista Pharmaceuticals: Our Verdict

KalVista's valuation continues to drift but it has two things going for it: cash runway & catalysts.

KalVista: Cheap, Well-Funded, And Headed Towards Key Catalysts

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: KalVista Pharmaceuticals

Shares of KalVista have fallen nearly 30% this month due to sector weakness and insider sales (presumably).

Shares Of KalVista Are Nearing Buy Territory Again

News for KalVista Pharma Stock (KALV)